These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 12908351

  • 1. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
    Joosten AA, van Olffen GH, Hageman G.
    Ned Tijdschr Geneeskd; 2003 Jul 26; 147(30):1470-2. PubMed ID: 12908351
    [Abstract] [Full Text] [Related]

  • 2. [Listeria meningitis in a patient with Crohn's disease--a seldom, but clinically relevant adverse event of therapy with infliximab].
    Dederichs F, Pinciu F, Gerhard H, Eveld K, Stallmach A.
    Z Gastroenterol; 2006 Aug 26; 44(8):657-60. PubMed ID: 16902896
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone.
    Parihar V, Maguire S, Shahin A, Ahmed Z, O'Sullivan M, Kennedy M, Smyth C, Farrell R.
    Ir J Med Sci; 2016 Nov 26; 185(4):965-967. PubMed ID: 26358724
    [Abstract] [Full Text] [Related]

  • 5. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
    Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE.
    Gut; 2008 Mar 26; 57(3):425; author reply 425-6. PubMed ID: 18268059
    [No Abstract] [Full Text] [Related]

  • 6. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
    Izbéki F, Nagy F, Szepes Z, Kiss I, Lonovics J, Molnár T.
    Inflamm Bowel Dis; 2008 Mar 26; 14(3):429-31. PubMed ID: 17973302
    [No Abstract] [Full Text] [Related]

  • 7. How to improve the safety of biologic therapy in Crohn's disease.
    Ferkolj I.
    J Physiol Pharmacol; 2009 Dec 26; 60 Suppl 7():67-70. PubMed ID: 20388947
    [Abstract] [Full Text] [Related]

  • 8. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.
    Jain VV, Evans T, Peterson MW.
    Respir Med; 2006 Jul 26; 100(7):1291-3. PubMed ID: 16545951
    [Abstract] [Full Text] [Related]

  • 9. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
    Minnee RC, Stokkers P, Riemens SC, Hommes DW.
    Ned Tijdschr Geneeskd; 2005 Oct 08; 149(41):2290-5. PubMed ID: 16240855
    [Abstract] [Full Text] [Related]

  • 10. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P, Van Assche G, Vermeire S.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):451-63. PubMed ID: 16441465
    [Abstract] [Full Text] [Related]

  • 11. Mucormycosis in a Crohn's disease patient treated with infliximab.
    Wall GC, Leman BI.
    Digestion; 2009 Feb 15; 80(3):182-4. PubMed ID: 19776582
    [Abstract] [Full Text] [Related]

  • 12. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A, Di Prima L, Pirrone G, Ambrosiano G, Noto D, Cefalù AB.
    Recenti Prog Med; 2006 Feb 15; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [Abstract] [Full Text] [Related]

  • 13. [Listeria meningitis as complication of treatment with infliximab in a patient with Crohn's disease].
    Osuna Molina R, Ferrer Ríos T, Gallego Gallegos R, Ramos Lora M, Ynfante Ferrús M, Figueruela López B.
    Rev Esp Enferm Dig; 2006 Jan 15; 98(1):60-1. PubMed ID: 16555939
    [No Abstract] [Full Text] [Related]

  • 14. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
    Vadikolias K, Kouklakis G, Heliopoulos I, Argyropoulou P, Papanas N, Tzilonidou M, Prassopoulos P, Piperidou H.
    Eur J Gastroenterol Hepatol; 2007 Feb 15; 19(2):159-62. PubMed ID: 17273002
    [Abstract] [Full Text] [Related]

  • 15. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
    Moiton MP, Richez C, Dumoulin C, Mehsen N, Dehais J, Schaeverbeke T.
    Clin Microbiol Infect; 2006 Dec 15; 12(12):1151-3. PubMed ID: 17121619
    [Abstract] [Full Text] [Related]

  • 16. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec 15; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 17. [A case of acute and necrotizing cutaneous Mycobacterium marinum infection in a patient treated with infliximab for Crohn's disease].
    Guyot A, Begon E, Abramowitz L, Landry J, Marinho E, Descamps V, Crickx B.
    Ann Dermatol Venereol; 2009 Nov 15; 136(11):806-10. PubMed ID: 19917434
    [Abstract] [Full Text] [Related]

  • 18. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H.
    J Dermatol; 2007 Jul 15; 34(7):468-72. PubMed ID: 17584325
    [Abstract] [Full Text] [Related]

  • 19. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F.
    Scand J Gastroenterol; 2006 Sep 15; 41(9):1064-72. PubMed ID: 16938720
    [Abstract] [Full Text] [Related]

  • 20. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J.
    Gut; 2009 Apr 15; 58(4):477-8. PubMed ID: 19299379
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.